Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Revista Ciencias de la Salud
versión impresa ISSN 1692-7273
Resumen
BERNAL-CAMARGO, Diana Rocío; GAITAN-BOHORQUEZ, Julio César y LEON-ROBAYO, Édgar Iván. Biosimilar Medicines in Colombia: An Approach from the Informed Consumption. Rev. Cienc. Salud [online]. 2018, vol.16, n.2, pp.311-339. ISSN 1692-7273. https://doi.org/10.12804/revistas.urosario.edu.co/revsalud/a.6772.
Introduction:
This article presents an analysis of biosimilar drugs in Colombia, aiming at critically analyzing whether the consumption of biosimilar drugs in Colombia is fully informed or if it rather is characterized for its lack of information. Informed consumption in the sense of taking into account the quality and quantity of the information circulating in relation to the availability and affordability (prices) of biosimilar drugs.
Development:
This is a qualitative documentary analysis, based on the review of databases such as Pubmed, Scopus, Scielo, Vlex and Redalyc, and sanitary databases of drugs regulatory agencies (FDA, EMA and the Colombian Invima) and the Vademecum Med Informatica. One of the biosimilars authorized by FDA and four of those by EMA were also registered before by the Invima. However, the number of Invima authorized biosimilars is higher than that authorized by FDA and EMA. It is also important to highlight the fact that any biosimilar is not registered as such neither before the Invima nor before any other official or commercial source. Out of the biological reference products with biosimilars, twelve have regulated price and seven have been authorized at least once via court ruling.
Conclusions:
Although the regulations are progressive in relation to the access to biosimilars and, consequently, to their biological pioneers, the system still has legal, availability and information barriers that undermine the protection and effectiveness of the right to health.
Palabras clave : biosimilar drugs; biological medicines; informed consumption; the right to health; intellectual property rights; drug regulatory agencies; barriers to access to medicines.